ClinicalTrials.gg
Not yet recruitingNCT03875105Updated Aug 16, 2023

Daily Living Activities and Exercise Capacity in Lipid Storage Diseases

An observational study in Lipid Storage Disease, sponsored by Istanbul University. Not yet recruiting at 1 site in Turkey. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-16.

Sponsored by Istanbul University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Lipid Storage Diseases (LSD) is a group of metabolic diseases that are manifested by exercise intolerance or muscle weakness, sometimes accompanied by systemic findings, which develop in some stages of muscle contraction due to necessary lipid transfer or destruction pathways. Exercise intolerance in LSD can limit not only physical activity but also daily activities. In the literature, no study evaluated the activities of daily living in patients with LSD. The aim of this study was to investigate the effect of exercise capacity and daily living activities on the clinical features of LSD patients.

Read the detailed description

Pulmonary functions are affected negatively in Lipid Storage Diseases (LSD). It was shown that respiratory muscle strength and peak cough flow decreased in these cases. Other respiratory system problems can be listed as; diaphragmatic dysfunction, hypoxemia, and hypercapnia. Routine evaluation of respiratory function in LSD is recommended. A limited number of studies have shown that exercise tolerance is limited by the blockage of fat oxidation on the basis of muscle weakness and fatigue in LSD. Although the assessment of exercise capacity is also an important indicator of heart-lung capacity monitoring, exercise capacity is not routinely measured in patients with LSD. Exercise intolerance can limit not only physical activity but also daily activities. In the literature, the investigator's did not find any study evaluating the activities of daily living in patients with LSD. The aim of this study was to investigate the effect of exercise capacity and daily living activities on the clinical features of LSD patients.

02

Conditions studied

  • Lipid Storage Disease

Browse trials for

Keywords

  • exercise capacity
  • activities of daily living
03

In context

Lipidoses

16 studies on the registry are indexed under Lipidoses; 3 are open to participants now.

Browse Lipidoses studies →

Lead sponsor

Istanbul University is the lead sponsor of 514 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

25 patients who were diagnosed with Lipid Storage Disease at Istanbul University Istanbul Medical Faculty Neurology and Chest Diseases Departments will be invited to the study. The study will be continued in Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being diagnosed with Lipid storage disease clinically and histopathologically.

Exclusion criteria

Exclusion Criteria:

  • Severe pulmonary parenchymal disease,
  • Cardiac problems
  • Renal or hepatic dysfunction
  • Uncontrolled hypothyroidism
  • Acute infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. 6 minutes walking test

    Exercise capacity will be evaluated with 6 minutes walking test

    Time frame: 1 day

Secondary outcomes

  1. Activity limitation (ACTIVLIM) questionnaire

    Activities of daily living will be evaluated Activlim questionnaire. The questionnaire is consists of 22 questions. Minimum score is 0 and total score is 88. Higher scores indicate worse conditions.

    Time frame: 1 day

  2. Rivermead mobility index

    Mobility will be evaluated with Rivermead mobility index. The questionnaire consists of 14 questions. Minimum score is 0, maximum score is 15. Higher scores indicate better conditions.

    Time frame: 1 day

  3. Hand held dinamometer

    Hand held dinamometer will be used for the measurement of upper and lower muscle strength.

    Time frame: 1 day

07

Study locations

1 site
  • Istanbul University
    Istanbul, Turkey
    • Goksen Kuran Aslan, Assoc.Prof. · Contactgoksenkuran@yahoo.com · +90 (212) 414 15 28
    • Buket Akinci, Assist.Prof. · Sub investigator
    • Esen Kiyan, Prof.Dr. · Sub investigator
    • Hacer Durmus Tekce, Assoc.Prof. · Sub investigator
08

References and documents

Publications

  • Bingol Z, Tekce HD, Sagcan G, Serdaroglu P, Kiyan E. Pulmonary functions and sleep-related breathing disorders in lipid storage disease. Sleep Breath. 2018 Dec;22(4):1137-1142. doi: 10.1007/s11325-018-1647-1. Epub 2018 Mar 1. PubMed 29497949 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 14, 2019
StartEst.
Sep 2, 2023
Primary completionEst.
Sep 4, 2024
CompletionEst.
Nov 5, 2024
Last update
Aug 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03875105
Collaborators
Biruni University
Responsible party
Goksen Kuran Aslan (Associated Proffesor, Istanbul University) — Principal investigator
First posted
Mar 14, 2019
Start date
Sep 2, 2023 (estimated)
Primary completion
Sep 4, 2024 (estimated)
Completion
Nov 5, 2024 (estimated)
Last update
Aug 16, 2023

Study contacts

Goksen Kuran Aslan, Assoc.Prof
Contact
goksenkuran@yahoo.com
+90 (212) 414 15 28 ext. 40167
Goksen Kuran Aslan, Assoc.Prof.
principal investigator · Istanbul University - Cerrahpasa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion